Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1983 Mar 1;157(3):828–842. doi: 10.1084/jem.157.3.828

Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen

PMCID: PMC2186954  PMID: 6403649

Abstract

The ability of monoclonal antibodies against the Thy-1.1 differentiation antigen to inhibit the growth of transplanted syngeneic AKR/J SL2 leukemic cells has been previously demonstrated. In the present study we further examined therapy with monoclonal antibody of the IgG2a isotype, which was the most effective isotype studied. Intravenous infusion of ascites fluid containing the anti-Thy-1.1 monoclonal antibody 19-E12 1-2 h after tumor implantation led to inhibition of the growth of 3 X 10(5) but not 3 X 10(6) syngeneic SL2 leukemic cells. The achievement of the maximal therapeutic effect required the infusion of a dose containing 3.2 mg of antibody, which inhibited the growth of a subcutaneous inoculum of 3 X 10(5) SL2 leukemic cells in 83% of treated mice. Multiple doses of antibody were no more effective than a single dose given shortly after tumor implantation. The infusion of this relatively large 3.2-mg dose of antibody was required to infiltrate the subcutaneous space and saturate surface Thy-1.1 sites on leukemic cells in a subcutaneous tumor nodule. The failure of antibody to inhibit larger numbers of tumor cells was investigated. Growth of a subcutaneous tumor nodule in mice challenged with more than 3 X 10(5) cells resulted from the growth of Thy-1.1- bearing cells in spite of the presence of the infused anti-Thy-1.1 antibody on their surfaces. In contrast, metastatic growth was due to the emergence of variant leukemic cells lacking the Thy-1.1 antigen. Thus, treatment of transplanted T leukemic cells with an IgG2a anti-Thy- 1.1 monoclonal antibody was effective in eliminating 3 X 10(5) antigen- bearing leukemic cells from the subcutaneous space and was very effective in preventing metastasis of leukemic cells expressing the target Thy-1.1 antigen. Therapy was limited by the failure of host mechanisms to eliminate larger numbers of subcutaneous leukemic cells coated with the infused antibody and by the emergence of variant leukemic cells lacking the target antigen.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blythman H. E., Casellas P., Gros O., Gros P., Jansen F. K., Paolucci F., Pau B., Vidal H. Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. Nature. 1981 Mar 12;290(5802):145–146. doi: 10.1038/290145a0. [DOI] [PubMed] [Google Scholar]
  2. Ey P. L., Prowse S. J., Jenkin C. R. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978 Jul;15(7):429–436. doi: 10.1016/0161-5890(78)90070-6. [DOI] [PubMed] [Google Scholar]
  3. Herlyn D. M., Steplewski Z., Herlyn M. F., Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980 Mar;40(3):717–721. [PubMed] [Google Scholar]
  4. Johnson R. J., Siliciano R. F., Shin H. S. Suppression of antibody-sensitized tumor cells by macrophages: insufficient supply or activation of macrophages within large tumors. J Immunol. 1979 Feb;122(2):379–382. [PubMed] [Google Scholar]
  5. Kirch M. E., Hammerling U. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells. J Immunol. 1981 Aug;127(2):805–810. [PubMed] [Google Scholar]
  6. Krolick K. A., Villemez C., Isakson P., Uhr J. W., Vitetta E. S. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5419–5423. doi: 10.1073/pnas.77.9.5419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  8. Langlois A. J., Matthews T., Roloson G. J., Thiel H. J., Collins J. J., Bolognesi D. P. Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction. J Immunol. 1981 Jun;126(6):2337–2341. [PubMed] [Google Scholar]
  9. Lanier L. L., Babcock G. F., Raybourne R. B., Arnold L. W., Warner N. L., Haughton G. Mechanism of B cell lymphoma immunotherapy with passive xenogeneic anti-idiotype serum. J Immunol. 1980 Oct;125(4):1730–1736. [PubMed] [Google Scholar]
  10. Miller R. A., Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet. 1981 Aug 1;2(8240):226–230. doi: 10.1016/s0140-6736(81)90475-x. [DOI] [PubMed] [Google Scholar]
  11. Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., Antman K. H., Schlossman S. F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep;40(9):3147–3154. [PubMed] [Google Scholar]
  12. Nowinski R. C., Hays E. F., Doyle T., Linkhart S., Medeiros E., Pickering R. Oncornaviruses produced by murine leukemia cells in culture. Virology. 1977 Sep;81(2):363–370. doi: 10.1016/0042-6822(77)90152-0. [DOI] [PubMed] [Google Scholar]
  13. Ritz J., Pesando J. M., Sallan S. E., Clavell L. A., Notis-McConarty J., Rosenthal P., Schlossman S. F. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul;58(1):141–152. [PubMed] [Google Scholar]
  14. Roloson G. J., Haagensen D. E., Jr, Chambers C. A., Bolognesi D. P. Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus. J Immunol. 1981 Jun;126(6):2328–2331. [PubMed] [Google Scholar]
  15. Shin H. S., Economou J. S., Pasternack G. R., Johnson R. J., Hayden M. L. Antibody-mediated suppression of grafted lymphoma. IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody. J Exp Med. 1976 Nov 2;144(5):1274–1283. doi: 10.1084/jem.144.5.1274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shin H. S., Hayden M., Langley S., Kaliss N., Smith M. R. Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts. J Immunol. 1975 Apr;114(4):1255–1263. [PubMed] [Google Scholar]
  17. Thorpe P. E., Brown A. N., Ross W. C., Cumber A. J., Detre S. I., Edwards D. C., Davies A. J., Stirpe F. Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. Eur J Biochem. 1981 Jun 1;116(3):447–454. doi: 10.1111/j.1432-1033.1981.tb05356.x. [DOI] [PubMed] [Google Scholar]
  18. Trowbridge I. S., Domingo D. L. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature. 1981 Nov 12;294(5837):171–173. doi: 10.1038/294171a0. [DOI] [PubMed] [Google Scholar]
  19. Wright P. W., Bernstein I. D. Serotherapy of malignant disease. Prog Exp Tumor Res. 1980;25:140–162. [PubMed] [Google Scholar]
  20. Young W. W., Jr, Hakomori S. I. Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo. Science. 1981 Jan 30;211(4481):487–489. doi: 10.1126/science.7455688. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES